GlassScriptPhysician profile
Venkatadri C Beeki
NPI 1619960044
$4,083.84
in general payments reported to CMS, 2019-2025
38 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $547 · 2021: $576 · 2022: $648 · 2023: $488 · 2024: $535 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231 · Education: $50.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.69 |
| Education | $50.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $540.66 | 2019-2023 | Provenge |
| Janssen Biotech, INC. | $441.49 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Genzyme Corporation | $250.34 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $238.51 | 2019-2025 | Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $238.26 | 2019-2024 | |
| Pfizer INC. | $229.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $194.27 | 2019-2022 | |
| Daiichi Sankyo INC. | $137.11 | 2020-2021 | |
| Glaxosmithkline, LLC. | $130.87 | 2020-2025 | Ojjaara, Shingrix |
| Lilly USA, LLC | $125.36 | 2021 | |
| Taiho Oncology, INC. | $125.00 | 2019 | |
| Gilead Sciences, INC. | $117.07 | 2021-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $110.69 | 2021-2025 | |
| Astellas Pharma US INC | $99.00 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $98.31 | 2019-2024 | Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $86.79 | 2019-2023 | Imbruvica |
| Abbvie INC. | $77.29 | 2024-2025 | |
| Amgen INC. | $69.17 | 2019-2022 | |
| Seagen INC. | $61.51 | 2021-2023 | Padcev |
| Epizyme, INC. | $50.37 | 2020-2021 | |
| Stemline Therapeutics INC. | $47.99 | 2023-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $43.78 | 2019-2022 | |
| Blueprint Medicines Corporation | $40.43 | 2020-2022 | |
| Array Biopharma INC | $36.41 | 2024 | Tukysa, Braftovi, Mektovi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.48 | 2019-2021 | |
| Clovis Oncology, INC. | $29.20 | 2019-2020 | |
| Sobi, INC | $24.04 | 2024 | |
| Merck Sharp & Dohme LLC | $22.74 | 2024 | Keytruda |
| Celgene Corporation | $18.72 | 2019 | |
| Exelixis INC. | $17.67 | 2021 | |
| Tesaro, INC. | $16.98 | 2019 | |
| Incyte Corporation | $16.56 | 2021 | |
| Kite Pharma, INC. | $14.94 | 2022 | |
| Telix Pharmaceuticals | $14.85 | 2023 | Illuccix |
| Beigene USA, INC. | $13.40 | 2020 | |
| Eisai INC. | $11.53 | 2021 | |
| Puma Biotechnology, INC. | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkatadri Beeki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.